ClinicalTrials.gov Chelation Studies | Chelation Therapy and Oral Chelation

ClinicalTrials.gov Chelation Studies

1   Completed   Combination Iron Chelation Therapy
Conditions:   Iron Overload;   Thalassemia
Intervention:   Drug: Combination Iron Chelation Therapy
 
2   Completed   Long-Term Lead Chelation Therapy and Progressive Renal Insufficiency
Condition:   Urologic Disease
Intervention:   Drug: calcium disodium EDTA (edetate calcium disodium)
 
3   Active, not recruiting   Penicillamine Chelation for Children With Lead Poisoning
Conditions:   Lead Poisoning;   Vitamin D Deficiency
Interventions:   Device: d-penicillamine;   Drug: placebo
 
4   Active, not recruiting   An Extension Study of Iron Chelation Therapy With Deferasirox in β-Thalassemia Patients With Transfusional Iron Overload
Condition:   Transfusional Iron Overload in β-Thalassemia
Intervention:   Drug: Deferasirox
 
5   Active, not recruiting   Mercury Chelation to Treat Autism
Conditions:   Autism;   Asperger’s Disorder;   Child Development Disorders, Pervasive
Intervention:   Drug: DMSA
 
6   Active, not recruiting   Iron Chelation Therapy With Deferasirox in β-Thalassemia Major Pediatric Patients With Transfusional Iron Overload
Condition:   Transfusional Iron Overload in β-Thalassemia Major
Intervention:   Drug: Deferasirox
 
7   Active, not recruiting   Extension Study of Iron Chelation Therapy With Deferasirox in β-Thalassemia and Other Patients With Rare Chronic Anemia and Transfusional Iron Overload
Condition:   Transfusional Iron Overload in Patients With Chronic Anemia
Intervention:   Drug: Deferasirox
 
8   Active, not recruiting   Iron-Chelating Therapy and Friedreich Ataxia
Condition:   Friedreich Ataxia
Intervention:   Drug: Iron chelating intervention
 
9   Completed   Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone
Conditions:   Anemia (Iron-Loading);   Beta-Thalassemia;   Hematologic Diseases;   Hemoglobinopathies;   Thalassemia;   Iron Overload
Intervention:   Drug: chelation therapy
 
10   Completed   Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload
Condition:   Transfusional Iron Overload
Intervention:   Drug: Deferasirox
 
11   Active, not recruiting   Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major
Condition:   Beta-Thalassemia
Intervention:   Drug: deferiprone
 
12   Completed   CellCept/Iron Study: The Iron Ion-Mycophenolate Mofetil Chelation Complex Interaction in Renal Allograft Recipients
Condition:   End Stage Renal Disease
Intervention:    
 
13   Active, not recruiting   A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-Dependent Iron Overload
Condition:   Transfusion-Dependent Iron Overload
Intervention:   Drug: Deferasirox
 
14   Active, not recruiting   Efficacy and Safety of Deferasirox in Patients With Transfusion-Dependent Iron Overload
Condition:   Transfusion-Dependent Iron Overload
Intervention:   Drug: Deferasirox
 
15   Completed   Efficacy Study in Removing Excess Iron From the Heart
Conditions:   Thalassemia Major;   Hemosiderosis
Interventions:   Drug: Ferriprox (deferiprone);   Drug: Desferal (deferoxamine)
 
16   Active, not recruiting   Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients
Conditions:   Myelodysplastic Syndrome;   Iron Overload
Intervention:   Drug: Deferasirox
 
17   Active, not recruiting   Cardiac Function in Patients With Hereditary Hemochromatosis
Condition:   Hemochromatosis
Intervention:    
 
18   Active, not recruiting   A 1-Year Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effects on Liver Iron Concentration of Deferasirox and Deferoxamine in Children and Adults With Sickle Cell Disease and Transfusional Hemosiderosis
Condition:   Sickle Cell Disease
Intervention:   Drug: Deferasirox
 
19   Active, not recruiting   Extension Study on Efficacy and Safety of Deferasirox Treatment in Patients With Beta-Thalassemia and Transfusional Hemosiderosis
Condition:   Beta-Thalassemia Major
Intervention:   Drug: ICL670; deferasirox
 
20   Completed   Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis
Condition:   Idiopathic Pulmonary Fibrosis
Intervention:   Drug: Tetrathiomolybdate
 
21   Active, not recruiting   Treatment of Lead-Exposed Children Trial
Condition:   Lead Exposure
Intervention:    
 
22   Completed   Hydroxyurea to Treat Beta-Thalassemia (Cooley’s Anemia)
Conditions:   Beta Thalassemia;   Hemoglobinopathy
Intervention:   Drug: Hydroxyurea
 
23   Completed   5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia
Condition:   Beta Thalassemia
Intervention:   Drug: 5-Azacytidine
 
24   Completed   Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis
Conditions:   Anemia (Iron-Loading);   Beta-Thalassemia;   Hematologic Diseases;   Hemoglobinopathies;   Thalassemia;   Iron Overload;   Hemochromatosis
Intervention:   Drug: deferoxamine
 
25   Completed   Thalassemia (Cooley’s Anemia) Clinical Research Network (TCRN)
Conditions:   Anemia, Cooley’s;   Beta-Thalassemia;   Hematologic Diseases;   Thalassemia;   Osteoporosis;   Iron Overload;   Hypertension, Pulmonary
Interventions:   Drug: Deferoxamine;   Drug: Deferiprone;   Drug: Arginine;   Drug: Sildenafil;   Drug: Decitabine
 
26   Active, not recruiting   Deferoxamine for the Treatment of Hemochromatosis
Conditions:   Diabetes Mellitus;   Heart Disease;   Hemochromatosis;   Thalassemia
Intervention:    
 
27   Completed   Monoclonal Antibody Therapy in Treating Patients With Leukemia
Conditions:   Lymphoma;   Radiation Toxicity
Interventions:   Drug: pentetic acid calcium;   Drug: yttrium Y 90 daclizumab;   Procedure: monoclonal antibody therapy;   Procedure: radioimmunotherapy;   Procedure: radioprotection
 
28   Completed   Safety & Efficacy of ICL670 Vs. Deferoxamine in Beta-Thalassemia Patients With Iron Overload Due to Blood Transfusions
Condition:   Beta-Thalassemia
Interventions:   Drug: ICL670;   Drug: deferoxamine
 
29   Completed   Study of Deferasirox in Iron Overload From Beta-Thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias
Conditions:   Beta-Thalassemia;   Myelodysplastic Syndromes;   Fanconi Syndrome;   Anemia, Diamond-Blackfan;   Anemia, Aplastic
Intervention:   Drug: Deferasirox
 
30   Completed   Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions
Condition:   Anemia, Sickle Cell
Interventions:   Drug: ICL670;   Drug: deferoxamine
 
31   Active, not recruiting   Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients
Conditions:   Sickle Cell Disease;   Iron Overload;   Hemolytic Anemia
Intervention:   Drug: Deferasirox
 
32   Active, not recruiting   Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients
Conditions:   Myelodysplastic Syndromes;   Iron Overload
Intervention:   Drug: deferasirox
 
33   Completed   Chromium Picolinate for the Treatment of Metabolic Syndrome
Conditions:   Metabolic Syndrome X;   Prediabetic State;   Insulin Resistance;   Obesity;   Metabolic Diseases
Intervention:   Drug: Chromium picolinate
 
34   Completed   A Study of Long-Term Treatment With Deferasirox in Patients With Beta-Thalassemia and Transfusional Hemosiderosis
Conditions:   Beta-Thalassemia;   Hemosiderosis
Intervention:   Drug: deferasirox
 
35   Active, not recruiting   Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload
Conditions:   Thalassemia;   Sickle Cell Disease;   Diamond Blackfan Anemia;   Myelofibrosis
Intervention:   Drug: Deferasirox
 
36   Completed   Chromium and Insulin Action
Condition:   Type 2 Diabetes
Intervention:   Drug: Chromium Picolinate
 
37   Completed   Efficacy and Safety Study of Chromium Picolinate + Biotin on Glucose and Cholesterol Control in T2DM
Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Chromium Picolinate (600 mcg Cr) + biotin (2 mg)
 
38   Completed   Assess Feasibility of an Acellular Pertussis Vaccine (Pa) Given Soon After Birth, Followed by 3-Dose Primary Vaccination With the DTPa-HBV-IPV/Hib Vaccine
Conditions:   Diphtheria;   Tetanus;   Pertussis;   Hepatitis B;   Poliomyelitis;   Hib Disease
Interventions:   Biological: Pertussis vaccine;   Biological: DTPa-HBV-IPV/Hib
 
39   Completed   A 30 Day Acute Efficacy and Safety Study of Chromium Picolinate + Biotin on Glycemic Control in Overweight or Obese Subjects With T2DM
Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Chromium Picolinate (600 mcg Cr+3) + biotin (2 mg)
 
40   Completed   Immunogenicity & Safety of GSK’s Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Schedules
Conditions:   Healthy;   Infant
Intervention:   Biological: DTPa-HBV-IPV/Hib vaccine
 
41   Completed   Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals’ DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants
Conditions:   Diphtheria;   Tetanus;   Pertussis;   Hepatitis B;   Poliomyelitis;   Haemophilus Influenza Type b Disease
Intervention:   Biological: DTPa-HBV-IPV/Hib vaccine
 
42   Active, not recruiting   Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine
Conditions:   Healthy;   Infant
Intervention:   Biological: DTPa-HBV-IPV/Hib vaccine
 
43   Terminated   Pilot Trial of Chromium-Metformin Combination in Type 2 Diabetes
Condition:   Type 2 Diabetes
Intervention:   Drug: Chromium Picolinate
 
44   Active, not recruiting   Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients
Condition:   Hemochromatosis
Interventions:   Drug: Deferiprone (L1);   Drug: Desferrioxamine
 
45   Active, not recruiting   Iron-Fortified Whole Maize Flour Trial
Condition:   Anaemia
Intervention:   Drug: NaFeEDTA, Electrolytic Iron
 
46   Completed   Effect of a Potent Inducer Rifampicin on the Pharmacokinetics of Deferasirox in Healthy Volunteers
Condition:   Healthy
Interventions:   Drug: Deferasirox;   Drug: Rifampicin
 
47   Active, not recruiting   Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of Midazolam
Condition:   Healthy
Intervention:   Drug: Deferasirox
 
48   Active, not recruiting   Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA
Conditions:   Central Nervous System Tumors;   Brain Tumors
Interventions:   Drug: Gallium-67 Citrate;   Drug: In-111 DTPA
 
49   Completed   Effects of Chromium Picolinate on Food Intake
Conditions:   Obesity;   Atypical Depression
Intervention:   Drug: Chromium Picolinate
 
50   Completed   An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients
Condition:   HIV Infections
Intervention:   Drug: Ditiocarb sodium
Posted in Chelation Studies on Jun 9th, 2017, 1:39 pm by admin   

No comments yet. Be the first.

Leave a reply

You must be logged in to post a comment.